<DOC>
	<DOCNO>NCT00501540</DOCNO>
	<brief_summary>The purpose study learn effectiveness side effect lithium treatment subject low-grade neuroendocrine tumor .</brief_summary>
	<brief_title>Lithium Low-Grade Neuroendocrine Tumors</brief_title>
	<detailed_description>Lithium 300mg mouth , three time daily , escalate lithium level 0.8-1.0 ; Continue progressive disease/unacceptable toxicity ; Evaluate q 8 week .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Must histologically confirm metastatic lowgrade neuroendocrine neoplasm . Small cell lung cancer , paragangliomas pheochromocytoma exclude . Pathologic diagnosis must confirm UWCCC . Grading must confirm pathologic review perform UWCCC . Must measurable disease Must radiographic evidence disease progression follow prior systemic therapy , chemoembolization , bland embolization , surgery , observation . Must ≥ 4 week completion major surgery , chemotherapy , systemic therapy local liver therapy study registration Must ≥ 3 week completion radiation therapy study registration The following laboratory value obtain within 14 day prior registration : Absolute neutrophils count ( ANC ) ≥ 1000/mm3 ; Platelets ≥ 75,000/mm3 ; Hemoglobin ≥ 8.0 g/dL ; Total bilirubin less equal 2.0 X upper limit normal ( ULN ) ; AST le equal 3 X ULN less equal 5 X ULN liver metastases present ; Creatinine le equal ULN ; Serum sodium within normal limit PS = 02 Capable understanding investigational nature , potential risk benefit fo study able provide valid inform consent . Must available tissue specimen analyze pathologic confirmation . Age ≥ 18 year . Women must pregnant lactating . Women childbearing potential sexually active male require use accepted effective method contraception . Patients must know history allergic reaction adverse reaction Lithium derivative . Patients allow concurrent chemotherapy radiation therapy . Patients exclude follow : Gastrointestinal tract disease result inability take oral medication ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , bowel obstruction , inability swallow tablet . History hypothyroid disease Significant , active cardiac disease Patients must take follow medication : diuretic , ACE inhibitor , NSAIDs ( except aspirin sulindac ) , neuroleptic , tetracycline , COX2 inhibitor , citalopram , clovoxamine , escitalopram , femoxetine , fluoxetine , fluvoxamine , paroxatine , sertraline , zimeldine . Must willing undergo tumor biopsy pre post therapy . Patients concurrent malignancy allow study long patient undergo active treatment disease . Patients already take Lithium reason allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>low-grade neuroendocrine tumor</keyword>
	<keyword>lithium</keyword>
</DOC>